Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Krešimir Blažičević"'
Autor:
Nataša Skočibušić, Andrej Belančić, Gordana Kenđel Jovanović, Marin Golčić, Davorin Herceg, Luka Simetić, Krešimir Blažičević
Publikováno v:
Biology and Life Sciences Forum, Vol 29, Iss 1, p 23 (2023)
Not all cancer patients respond to immunotherapy, and the variation in response may be attributed to an individual’s microbiome, which is profoundly influenced by dietary habits. Understanding and manipulating the microbiome through dietary interve
Externí odkaz:
https://doaj.org/article/abc8f1cebca944a4b8656116b381447f
Autor:
Pleština, Marin Golčić, Luka Simetić, Davorin Herceg, Krešimir Blažičević, Gordana Kenđel Jovanović, Ivan Dražić, Andrej Belančić, Nataša Skočibušić, Dora Palčevski, Igor Rubinić, Vera Vlahović-Palčevski, Tea Majnarić, Renata Dobrila-Dintinjana, Stjepko
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 3052
Immunotherapy has improved the prognosis of metastatic melanoma patients, although most patients do not achieve a complete response. While specific gut microbiome and dietary habits might influence treatment success, there is a lack of concordance be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::403e8c0d538da2f07a9ebd6db504951d
Autor:
Marin Golčić, Tatjana Ladenhauser, Tea Majnarić, Krešimir Blažičević, Davorin Herceg, Lukaa Simetić
Publikováno v:
Anti-Cancer Drugs
Volume 32
Volume 32
Objectives Soft-tissue sarcomas (STSs) are a heterogeneous group of rare malignancies. Treatment for advanced STS usually starts with anthracycline-based therapies, with no clear sequence for further treatment. A preferred option is trabectedin, espe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f85a81b62611c33739fe0d906d4815f0
https://www.bib.irb.hr/1158133
https://www.bib.irb.hr/1158133
Publikováno v:
Anticancer research. 40(4)
BACKGROUND/AIM There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear. PATIENT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aeba5460e3d298bbebe4cc5775d06c9
https://pubmed.ncbi.nlm.nih.gov/32234909
https://pubmed.ncbi.nlm.nih.gov/32234909